A Phase III, Prospective, Open-label, Multi-center Trial of Ferric Derisomaltose in Children 0 to <18 Years of Age With Iron Deficiency Anemia Due to NDD-CKD or With Iron Deficiency Anemia Who Are Intolerant or Unresponsive to Oral Iron
Latest Information Update: 28 May 2025
At a glance
- Drugs Ferric derisomaltose (Primary)
- Indications Iron deficiency anaemia
- Focus Registrational; Therapeutic Use
- Sponsors Pharmacosmos
Most Recent Events
- 24 Feb 2025 Planned End Date changed from 30 Jun 2025 to 30 Apr 2026.
- 24 Feb 2025 Planned primary completion date changed from 30 Apr 2025 to 30 Apr 2026.
- 18 Oct 2024 Planned End Date changed from 30 Jun 2024 to 30 Jun 2025.